Prostate Cancer

News and new technology innovations concerning how imaging technology can help diagnose and treat prostate cancer can be found on this channel.

The American Society for Radiation Oncology (ASTRO) issued the following statement from ASTRO Board of Directors Chair Laura A. Dawson, M.D., FASTRO, in response to today's announcement that President Joe Biden will reignite the Cancer Moonshot initiative to accelerate the rate of progress in the nation's fight against cancer
News | Radiation Oncology
Radiation Oncologists Applaud Biden-Harris Administration's Renewed Commitment to Cancer Moonshot

February 3, 2022 — The American Society for Radiation Oncology (ASTRO) issued the following statement from ASTRO Board ...

Time February 03, 2022
arrow
Urgent and immediate action must be taken to ensure more effective and equitable implementation of cancer screening, according to a report released today by the President's Cancer Panel.
News | Radiology Imaging
President's Cancer Panel Calls for Urgent Action to Address Gaps in Cancer Screening Uptake

February 2, 2022 — Urgent and immediate action must be taken to ensure more effective and equitable implementation of ...

Time February 02, 2022
arrow
PET disease extent in EAU BCR low-risk patients, EAU BCR high-risk patients, and BCP patients (A) and predictors of PET M1 disease (B). OR = odds ratio. Image courtesy of Justin Ferdinandus, Wolfgang P. Fendler, Andrea Farolfi, et al.
News | Prostate Cancer
PSMA PET Validates EAU Classification System to Determine Risk of Prostate Cancer Recurrence

January 24, 2022 — New research has confirmed the accuracy of the novel European Association of Urology (EAU) risk ...

Time January 24, 2022
arrow
For the first time, researchers led by a team from the UCLA Jonsson Comprehensive Cancer Center used prostate cancer patients’ DNA to create a model that appears to predict who will have side effects from radiation.   
News | Prostate Cancer
Genetics Predicts Toxic Side Effects to Prostate Cancer Radiotherapy

January 19, 2022 — For the first time, researchers led by a team from the UCLA Jonsson Comprehensive Cancer Center used ...

Time January 19, 2022
arrow
A versatile light-sheet microscope developed at the University of Washington can provide surgeons with real-time pathology data to guide cancer-removal surgeries and can also non-destructively examine tumor biopsies in 3-D. Image courtesy of Mark Stone/University of Washington
News | Prostate Cancer
3-D Imaging Method May Help Doctors Better Determine Prostate Cancer Aggressiveness

December 10, 2021 — Prostate cancer is the most common cancer for men and, for men in the United States, it's the second ...

Time December 10, 2021
arrow
A new Harvey L. Neiman Health Policy Institute study of nearly 800,000 men found that between 2011 and 2017 black patients were 24% less likely than white patients to have a prostate MRI after receiving an elevated (prostate-specific antigen) PSA score
News | Prostate Cancer
Black Patients 24% Less Likely than White Patients to Have a Prostate MRI After Receiving an Elevated PSA Score

November 16, 2021 — A new Harvey L. Neiman Health Policy Institute study of nearly 800,000 men found that between 2011 ...

Time November 16, 2021
arrow
Videos | Radiation Oncology
VIDEO: MRI-Linac and PSMA PET Imaging Technologies Aids Therapy at GenesisCare

Walter Curran, Jr. M.D., FACR, FASCO, GenesisCare global chief medical officer, discusses three technologies that are ...

Time November 16, 2021
arrow
Veracyte Inc. announced that new data being presented at the American Society for Radiation Oncology (ASTRO) 2021 Annual Meeting suggest the company’s Decipher Prostate genomic classifier identifies patients with clinically high-risk prostate cancer who may require treatment intensification beyond standard-of-care therapy
News | Prostate Cancer
Data Presented at ASTRO 2021 Validate Prognostic Value of Decipher Prostate Genomic Test in Newly Diagnosed, Clinically High-Risk Prostate Cancer

November 11, 2021 — Veracyte Inc. announced that new data being presented at the American Society for Radiation Oncology ...

Time November 11, 2021
arrow
An individual patient data (IPD) meta-analysis of randomized, controlled clinical trials provides strong evidence for the addition of androgen deprivation therapy (ADT) to definitive radiotherapy (RT) for the treatment of prostate cancer, with the projection that adding ADT to the treatment of 10-15 men would prevent the development of distant metastasis in one man.
News | Prostate Cancer
International Meta-analysis Quantifies Impact of Three Prostate Cancer Therapy Intensification Strategies

October 28, 2021 — An individual patient data (IPD) meta-analysis of randomized, controlled clinical trials provides ...

Time October 28, 2021
arrow
A new meta-analysis finds that a genetic biomarker test accurately predicts how men with high-risk prostate cancer will respond to treatment with radiation and hormone therapy.
News | Prostate Cancer
Genetic Biomarker Test Predicts Recurrence and Survival Outcomes for Men with High-risk Prostate Cancer

October 25, 2021 — A new meta-analysis finds that a genetic biomarker test accurately predicts how men with high-risk ...

Time October 25, 2021
arrow
 Using fewer—but higher—doses of radiation to treat men with prostate cancer who had their prostates removed does not increase long-term side effects or lower their quality of life compared to conventional radiation treatment, a new, multi-institutional clinical trial shows.
News | Prostate Cancer
Shortened Course of Radiation Therapy Offers Similar Long-term Side Effects Following Prostate Removal Surgery

October 25, 2021 — Using fewer—but higher—doses of radiation to treat men with prostate cancer who had their prostates ...

Time October 25, 2021
arrow
Blue Earth Diagnostics, a Bracco company and recognized leader in the development and commercialization of innovative PET radiopharmaceuticals, announced presentations on Axumin (fluciclovine F 18) and 18F-fluciclovine at the upcoming American Society for Radiation Oncology (ASTRO) 2021 Annual Meeting
News | PET Imaging
Blue Earth Diagnostics Highlights Presentations on Axumin (Fluciclovine F 18) and 18F-Fluciclovine at ASTRO21

October 19, 2021 — Blue Earth Diagnostics, a Bracco company and recognized leader in the development and ...

Time October 19, 2021
arrow
Scientists have identified two subtypes of metastatic prostate cancer that respond differently to treatment, information that could one day guide physicians in treating patients with the therapies best suited to their disease.
News | Prostate Cancer
Metastatic Prostate Cancer Comes in Two Forms, Which Could Guide Treatment

September 24, 2021 — Scientists have identified two subtypes of metastatic prostate cancer that respond differently to ...

Time September 24, 2021
arrow
Paige Prostate, is the first artificial intelligence (AI)-based software designed to identify an area of interest on the prostate biopsy image with the highest likelihood of harboring cancer so it can be reviewed further by the pathologist if the area of concern has not been identified on initial review.
News | Digital Pathology
FDA Authorizes Software That Can Help Identify Prostate Cancer

September 22, 2021 — The U.S. Food and Drug Administration authorized marketing of software to assist medical ...

Time September 22, 2021
arrow
Bicameral legislation in U.S. House and Senate designed to address equity issues in patient access and affordability for innovative diagnostic radiopharmaceuticals
News | Radiopharmaceuticals and Tracers
Blue Earth Diagnostics Supports Timely Consideration and Passage of the FIND Act of 2021 by U.S. Congress

September 17, 2021 — Blue Earth Diagnostics, a Bracco company and recognized leader in the development and ...

Time September 17, 2021
arrow
Lantheus Holdings, Inc. and RefleXion Medical, Inc., today announced a development and commercialization collaboration to evaluate the use of piflufolastat F 18, Lantheus’ prostate-specific membrane antigen (PSMA)-targeted positron emission tomography (PET) imaging agent, to enable real-time therapeutic guidance of biology-guided radiotherapy (BgRT) in prostate cancer using the RefleXion X1 platform. 
News | PET Imaging
Lantheus and RefleXion Announce Collaboration with Potential to Improve Future Prostate Cancer Treatment

September 13, 2021 — Lantheus Holdings, Inc. and RefleXion Medical, Inc., today announced a development and ...

Time September 13, 2021
arrow
Researchers at Karolinska Institutet in Sweden recently reported that magnetic resonance imaging (MRI) could reduce overdiagnoses and thereby improve prostate cancer screening.
News | Prostate Cancer
MRI Can Cut Overdiagnoses in Prostate-cancer Screening by Half

August 13, 2021 — Researchers at Karolinska Institutet in Sweden recently reported that magnetic resonance imaging (MRI) ...

Time August 13, 2021
arrow
The Council on Radionuclides and Radiopharmaceuticals, Inc. (CORAR), along with physicians and patient organizations, supports the introduction of H.R. 4479, the “Facilitating Innovative Nuclear Diagnostics (FIND) Act of 2021” by Congressmen Scott Peters (D-CA), Bobby Rush (D-IL), Neal Dunn (R-FL) and Greg Murphy (R-NC).
News | Nuclear Imaging
Council on Radionuclides and Radiopharmaceuticals Supports the FIND Act of 2021

August 4, 2021 — The Council on Radionuclides and Radiopharmaceuticals, Inc. (CORAR), along with physicians and patient ...

Time August 04, 2021
arrow
Artificial intelligence-powered diagnostic tool spots asymptomatic prostate cancer in seconds
News | Prostate Cancer
New AI Tech for Early Detection of Prostate Cancer

July 19, 2021 — Prostate cancer is the most diagnosed cancer and a leading cause of death by cancer in Australian men ...

Time July 19, 2021
arrow
Most countries have not introduced nationwide prostate cancer screening, as current methods result in overdiagnoses and excessive and unnecessary biopsies. A new study by researchers at Karolinska Institutet in Sweden, which is published in The New England Journal of Medicine, indicates that screening by magnetic resonance imaging (MRI) and targeted biopsies could potentially cut overdiagnoses by half.
News | Prostate Cancer
MRI Can Cut Over-diagnoses in Prostate Cancer Screening by Half

July 12, 2021 — Most countries have not introduced nationwide prostate cancer screening, as current methods result in ...

Time July 12, 2021
arrow
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now